免疫检查点阻断在肾细胞癌中的应用。
Immune checkpoint blockade in renal cell carcinoma.
机构信息
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
出版信息
J Surg Oncol. 2021 Mar;123(3):739-750. doi: 10.1002/jso.26339.
Abstract
Immune checkpoint blockade (ICB) is the foundation of current first-line therapies in patients with metastatic renal cell carcinoma (mRCC) with the potential for eliciting long-lasting remissions. With the expanding arsenal of ICB-based therapies, biomarkers of response are urgently needed to guide optimal therapeutic selection. We review the data behind ICB therapy in RCC, emerging biomarkers of response, and the evolving role of surgery in patients with mRCC.
摘要
免疫检查点阻断 (ICB) 是转移性肾细胞癌 (mRCC) 患者目前一线治疗的基础，具有引发持久缓解的潜力。随着基于 ICB 的治疗方法不断增加，迫切需要反应生物标志物来指导最佳治疗选择。我们回顾了 RCC 中 ICB 治疗的相关数据、新的反应生物标志物以及手术在 mRCC 患者中的作用演变。
相似文献
1
Immune checkpoint blockade in renal cell carcinoma.
J Surg Oncol. 2021 Mar;123(3):739-750. doi: 10.1002/jso.26339.
2
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
Eur J Cancer. 2020 Aug;135:203-210. doi: 10.1016/j.ejca.2020.05.009. Epub 2020 Jun 27.
3
promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma.
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-002949.
4
Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
Eur Urol. 2023 Feb;83(2):145-151. doi: 10.1016/j.eururo.2022.10.004. Epub 2022 Oct 20.
5
Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Eur Urol. 2020 Aug;78(2):195-206. doi: 10.1016/j.eururo.2020.04.044. Epub 2020 May 4.
6
Biomarkers for evaluating the clinical response to immune checkpoint inhibitors in renal cell carcinoma (Review).
Oncol Rep. 2024 Dec;52(6). doi: 10.3892/or.2024.8823. Epub 2024 Oct 18.
7
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news.
Cancer Treat Rev. 2021 Sep;99:102239. doi: 10.1016/j.ctrv.2021.102239. Epub 2021 Jun 1.
8
Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Eur Urol Focus. 2023 Mar;9(2):275-277. doi: 10.1016/j.euf.2023.01.022. Epub 2023 Feb 10.
9
Checkpoint inhibitors in metastatic papillary renal cell carcinoma.
Cancer Treat Rev. 2021 Sep;99:102228. doi: 10.1016/j.ctrv.2021.102228. Epub 2021 May 20.
10
Current status and future perspective of immunotherapy for renal cell carcinoma.
Int J Clin Oncol. 2024 Aug;29(8):1105-1114. doi: 10.1007/s10147-023-02446-3. Epub 2023 Dec 18.
引用本文的文献
1
Revisiting Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Evidence of Survival Benefit with First-Line Immunotherapy and Targeted Therapy Regimens.
J Clin Med. 2025 Aug 6;14(15):5543. doi: 10.3390/jcm14155543.
2
Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors.
Urol Oncol. 2025 Mar;43(3):192.e21-192.e28. doi: 10.1016/j.urolonc.2024.10.013. Epub 2024 Nov 12.
3
2022 WUOF/SIU International Consultation on Urological Diseases: Genetics and Tumor Microenvironment of Renal Cell Carcinoma.
Soc Int Urol J. 2022 Nov;3(6):386-396. doi: 10.48083/BLPV3411.
4
VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis.
J Clin Invest. 2024 Apr 15;134(8):e173934. doi: 10.1172/JCI173934.
5
Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune Phenotype.
Cancers (Basel). 2023 Nov 22;15(23):5530. doi: 10.3390/cancers15235530.
6
HAPLN3 inhibits apoptosis and promotes EMT of clear cell renal cell carcinoma via ERK and Bcl-2 signal pathways.
J Cancer Res Clin Oncol. 2023 Jan;149(1):79-90. doi: 10.1007/s00432-022-04421-3. Epub 2022 Nov 14.
7
Radiogenomics in Clear Cell Renal Cell Carcinoma: A Review of the Current Status and Future Directions.
Cancers (Basel). 2022 Apr 22;14(9):2085. doi: 10.3390/cancers14092085.
8
The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas.
Front Endocrinol (Lausanne). 2021 Oct 21;12:726448. doi: 10.3389/fendo.2021.726448. eCollection 2021.
9
Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.
Int J Mol Sci. 2021 Jun 11;22(12):6290. doi: 10.3390/ijms22126290.
10
Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma.
Eur Urol Oncol. 2022 Feb;5(1):113-117. doi: 10.1016/j.euo.2021.04.002. Epub 2021 May 26.
本文引用的文献
1
Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial.
BMC Cancer. 2024 Feb 24;24(1):260. doi: 10.1186/s12885-024-11987-3.
2
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.
3
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.
Nat Med. 2020 Nov;26(11):1733-1741. doi: 10.1038/s41591-020-1044-8. Epub 2020 Sep 7.
4
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma.
Clin Cancer Res. 2020 Nov 1;26(21):5598-5608. doi: 10.1158/1078-0432.CCR-20-1408. Epub 2020 Aug 18.
5
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma.
Drugs. 2020 Aug;80(12):1169-1181. doi: 10.1007/s40265-020-01327-7.
6
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2019-000230.
7
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.
Nat Med. 2020 Jun;26(6):909-918. doi: 10.1038/s41591-020-0839-y. Epub 2020 May 29.
8
Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Eur Urol. 2020 Aug;78(2):195-206. doi: 10.1016/j.eururo.2020.04.044. Epub 2020 May 4.
9
Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
Eur Urol. 2020 Oct;78(4):615-623. doi: 10.1016/j.eururo.2020.04.038. Epub 2020 Apr 30.
10
Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.
BMC Med. 2020 Apr 20;18(1):87. doi: 10.1186/s12916-020-01549-2.
Zotero 插件